The authors suggest that people deficient in TYK2 may be predisposed to the formation of tumors. In addition, the absence of TYK2 in patients would predict a reduced response to type I interferons, drugs that are currently used to treat chronic myeloid leukemia. Therefore TYK2 deficiency may be relevant to the prognosis of patients as well as to their proper treatment and these patients may consequently have to be treated by alternative means.

TITLE: TYK2 is a key regulator of the surveillance of B lymphoid tumors

AUTHOR CONTACT:
Veronika Sexl
Department of Pharmacology
Medical University of Vienna
Vienna, Austria
Phone: 0043-1-4277-64137
Fax: 0043-1-4277-9641
E-mail: veronika.sexl@meduniwien.ac.at.
View the PDF of this article at: https://www.the-jci.org/press/22315.pdf

Copycat bacterial proteins turn the host immune response on itself in Guillain-Barr syndrome

Guillain Barr syndrome (GBS) is a rare disorder in which the body's immune system attacks part of the peripheral nervous system (an autoimmune response) causing weakness and tingling in the extremities that can spread to the entire body causing muscle paralysis that can be life-threatening. GB usually occurs a few days or weeks after the patient has had symptoms of respiratory or gastrointestinal viral infection. The most frequently identified triggering agent of GBS is the bacterium Campylobacter jejuni the leading cause of bacterial gastroenteritis worldwide.

The presence of bacterial antigens that mimic structures in human tissue
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-0497
Journal of Clinical Investigation
1-Dec-2004